# A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.

> **NCT05745142** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 376 (actual)

## Conditions studied

- Carcinoma, Renal Cell
- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Sunitinib

## Key facts

- **NCT ID:** NCT05745142
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-23
- **Primary completion:** 2023-02-23
- **Final completion:** 2023-02-23
- **Target enrollment:** 376 (ACTUAL)
- **Last updated:** 2024-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05745142

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05745142, "A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05745142. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*